Home Archives 2008 April

Monthly Archives: April 2008

Apologies for light posting as of late. I’ve been buried deep in revisions to Building Biotechnology and prepping for an upcoming talk. Writing is coming to a close, so soon I’ll be looking for external reviewers and case study contributions.

For those of you attending BIO 2008, I’ll be presenting in a session on trends in biotechnology communication on Friday morning.

Title: Scientific Communications – Trends and Liabilities
Track: Public Relations/Investor Relations
Date and Time: Friday, June 20 9:00 AM – 10:30 AM

Looking forward to seeing old colleagues and meeting new friends BIO.

I’m also working on an interesting story I want to post on the blog shortly. It’s about the challenges of managing founder/board relations in building a biotechnology company. Stay tuned…

The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract of each article:

Volume 14, Issue 2

Editorial

EditorialPDF
Yali Friedman

Articles

Export compliance for life sciencesPDF
John Avellanet
A new approach to improve technology commercialisation in university medical schoolsPDF
Courtney Price, Richard Huston, Arlen D Meyers
Biotechnology business models work: Evidence from the pharmaceutical marketplacePDF
J Leslie Glick
Valuing biotechnology companies: Does classification by technology type help?PDF
Jacqueline Loh, Robert Brooks
Risk management for the biotechnology industry: A Canadian perspectivePDF
Sandra Vanderbyl, Sherry Kobelak
Singapore’s biomedical sciences landscapePDF
Keat-Chuan Yeoh
Social responsibility for the use of genes, genomes and biotechnology in biotechnology companies: A commentary from the bioethical viewpointPDF
Yoshihiro Okada, Kazuo N Watanabe

Legal and Regulatory Updates

Legal and regulatory updatePDF
Gerry Kamstra, John Wilkinson

Conference Report

Maryland and Virginia unite at 2007 Mid-Atlantic Bio ConferencePDF
Harley King

Book Reviews

Book Review: Stem cell wars: Inside stories from the FrontlinesPDF
Grant H Skrepnek

 

Courtesy of DrugPatentWatch.com:

Drug Patent Expirations in April 2008
*Drugs may be covered by multiple patents

TradenameApplicantGeneric NamePatent NumberPatent Expiration
ACTINEXUniv Az Cancer Ctrmasoprocol4,695,590APR 17,2008
ACTINEXUniv Az Cancer Ctrmasoprocol5,008,294APR 15,2008
ESTROSTEP 21Warner Chilcottethinyl estradiol; norethindrone acetate5,010,070APR 23,2008
ESTROSTEP FEWarner Chilcottethinyl estradiol; norethindrone acetate5,010,070APR 23,2008
FEMPATCHParke Davisestradiol5,006,342APR 09,2008
LODINE XLWyeth Pharms Incetodolac4,966,768APR 30,2008
ORFADINSwedish Orphannitisinone5,006,158APR 09,2008
ZEMURONOrganon Usa Incrocuronium bromide4,894,369APR 13,2008

Courtesy of DrugPatentWatch.com